Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BRTXQNASDAQ:GHNASDAQ:OPCHNASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXQBioRestorative Therapies$1.71+4.2%$1.74$0.00▼$0.06$2.80B102.3662.17 million shs59,149 shsGHGuardant Health$48.76-2.5%$44.62$20.14▼$52.92$6.04B1.372.13 million shs362,121 shsOPCHOption Care Health$32.33+0.2%$32.06$21.39▼$35.53$5.29B0.741.87 million shs154,096 shsRDNTRadNet$55.770.0%$55.52$45.00▼$93.65$4.17B1.43680,464 shs63,709 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXQBioRestorative Therapies+3.80%+1.23%-1.20%-14.58%-19.21%GHGuardant Health+2.97%+0.93%+31.55%+9.05%+71.85%OPCHOption Care Health+3.90%+1.32%+2.71%-7.91%+12.56%RDNTRadNet+1.66%-1.38%-1.47%+9.98%-3.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRTXQBioRestorative TherapiesN/AN/AN/AN/AN/AN/AN/AN/AGHGuardant Health3.6853 of 5 stars2.53.00.04.31.42.50.6OPCHOption Care Health3.6707 of 5 stars2.43.00.04.22.51.70.6RDNTRadNet3.9836 of 5 stars3.82.00.04.61.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRTXQBioRestorative Therapies 0.00N/AN/AN/AGHGuardant Health 3.00Buy$53.7610.25% UpsideOPCHOption Care Health 2.88Moderate Buy$35.509.81% UpsideRDNTRadNet 3.50Strong Buy$69.6024.81% UpsideCurrent Analyst Ratings BreakdownLatest BRTXQ, OPCH, GH, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025OPCHOption Care HealthJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$36.006/13/2025GHGuardant HealthMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.006/13/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$69.006/12/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/6/2025GHGuardant HealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.005/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.005/1/2025GHGuardant HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $65.005/1/2025GHGuardant HealthTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $60.005/1/2025GHGuardant HealthBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$55.00 ➝ $60.005/1/2025GHGuardant HealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$53.00 ➝ $60.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRTXQBioRestorative Therapies$110K25,470.84N/AN/A($0.68) per share-2.51GHGuardant Health$739.02M8.17N/AN/A($1.13) per share-43.15OPCHOption Care Health$5.00B1.06$1.71 per share18.88$8.25 per share3.92RDNTRadNet$1.83B2.29$3.54 per share15.75$15.31 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRTXQBioRestorative Therapies-$12.52M-$1.07N/A∞N/AN/AN/AN/AN/AGHGuardant Health-$436.37M-$3.39N/AN/AN/A-53.82%-1,200.44%-26.77%8/6/2025 (Estimated)OPCHOption Care Health$211.82M$1.2426.0625.661.884.12%16.90%7.00%7/30/2025 (Estimated)RDNTRadNet$2.79M-$0.43N/A105.22N/A-1.73%1.41%0.48%8/6/2025 (Estimated)Latest BRTXQ, OPCH, GH, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million4/29/2025Q1 2025OPCHOption Care Health$0.36$0.40+$0.04$0.28$1.26 billion$1.33 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRTXQBioRestorative TherapiesN/AN/AN/AN/AN/AGHGuardant HealthN/AN/AN/AN/AN/AOPCHOption Care HealthN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRTXQBioRestorative TherapiesN/AN/AN/AGHGuardant HealthN/A4.113.76OPCHOption Care Health0.821.541.02RDNTRadNet0.872.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRTXQBioRestorative TherapiesN/AGHGuardant Health92.60%OPCHOption Care Health98.05%RDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipBRTXQBioRestorative Therapies12.20%GHGuardant Health6.10%OPCHOption Care Health0.64%RDNTRadNet5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRTXQBioRestorative Therapies71.64 billionN/ANot OptionableGHGuardant Health2,021123.89 million116.33 millionNot OptionableOPCHOption Care Health8,088163.75 million162.70 millionOptionableRDNTRadNet11,02175.03 million70.83 millionOptionableBRTXQ, OPCH, GH, and RDNT HeadlinesRecent News About These CompaniesEarly Detection Revolution: RadNet implements AI into low-dose CTJune 23 at 8:40 PM | ladowntownnews.comSG Americas Securities LLC Raises Position in RadNet, Inc. (NASDAQ:RDNT)June 22 at 3:12 AM | marketbeat.comRadNet (NASDAQ:RDNT) Upgraded by Wall Street Zen to "Hold" RatingJune 22 at 2:25 AM | americanbankingnews.comRadNet (NASDAQ:RDNT) Upgraded at Wall Street ZenJune 21, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital EffectivelyJune 20, 2025 | finance.yahoo.comRadNet, Inc. (NASDAQ:RDNT) Receives $69.60 Consensus Target Price from AnalystsJune 18, 2025 | americanbankingnews.comB. Riley Initiates Coverage on RadNet (NASDAQ:RDNT)June 16, 2025 | americanbankingnews.comRadNet, Inc. (NASDAQ:RDNT) Given Consensus Rating of "Strong Buy" by AnalystsJune 15, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Upgraded by B. Riley to Strong-Buy RatingJune 14, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Coverage Initiated by Analysts at B. RileyJune 13, 2025 | marketbeat.com1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Be Wary OfJune 12, 2025 | msn.comRadNet, Inc. Secures $100 Million Incremental Term Loan to Support Strategic Growth InitiativesJune 11, 2025 | quiverquant.comRadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate InitiativesJune 11, 2025 | globenewswire.comGAMMA Investing LLC Buys 80,396 Shares of RadNet, Inc. (NASDAQ:RDNT)June 11, 2025 | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) is Harbor Capital Advisors Inc.'s 4th Largest PositionJune 10, 2025 | marketbeat.comE. Ohman J or Asset Management AB Buys 5,300 Shares of RadNet, Inc. (NASDAQ:RDNT)June 7, 2025 | marketbeat.comRDNT Q1 Earnings Call: Severe Weather Disruptions and Ongoing Shift to Advanced Imaging Highlight ResultsJune 6, 2025 | msn.comRadNet Acquires See-Mode Technologies to Enhance AI Ultrasound ImagingJune 5, 2025 | insidermonkey.comRadNet Acquires Ultrasound Firm See-Mode TechnologiesJune 4, 2025 | marketwatch.comRadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound DiagnosticsJune 4, 2025 | globenewswire.comWellington Management Group LLP Trims Stake in RadNet, Inc. (NASDAQ:RDNT)June 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short InterestWhy Super Micro Computer's Upside Could Trigger a Short SqueezeBy Gabriel Osorio-Mazilli | June 3, 2025View Why Super Micro Computer's Upside Could Trigger a Short Squeeze3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherBRTXQ, OPCH, GH, and RDNT Company DescriptionsBioRestorative Therapies OTCMKTS:BRTXQ$1.71 +0.07 (+4.20%) As of 06/24/2025BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.Guardant Health NASDAQ:GH$48.76 -1.23 (-2.46%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Option Care Health NASDAQ:OPCH$32.29 +0.03 (+0.10%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.RadNet NASDAQ:RDNT$55.76 -0.02 (-0.03%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
